NORTH ADAMS, Mass. -- The creation of the new Lucian Leape Institute at the National Patient Safety Foundation (NPSF) was announced today at NPSF's annual Patient Safety Congress in Washington, D.C. Dr. Lucian Leape is a physician and adjunct professor of health policy at the Harvard School of Public Health, and is internationally recognized as a founder and leader of the patient safety movement. The National Patient
Safety Foundation's Annual Patient Safety Congress brings together patient safety experts, practitioners, patients and other stakeholders to share new strategies, research, and knowledge focused on improving the safety of the healthcare system.
The Lucian Leape Institute will function as a think tank and define strategic paths and calls to action for the field of patient safety, intended to provide vision and context for the many efforts underway within the healthcare system. Through its roundtables, it will issue reports that will guide the work of the field and challenge the system to address the issues critical to making the system safer.
"The National Patient Safety Foundation has been honored to work with Dr. Leape since our founding, and we are pleased to be able to recognize his leadership in the field through the establishment of this Institute," says Diane C. Pinakiewicz, president of the NPSF. "The work of the Institute will provide important guidance for the many improvement efforts underway in the field."
Source: National Patient Safety Foundation
  Â
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.